UCN-01 (7-hydroxystaurosporine) inhibits the growth of various malignant ce
ll lines in vitro and in vivo. In this study, a human small cell lung carci
noma subline resistant to UCN-01, SBC-3/UCN, was established and characteri
zed. SBC-3/ UCN cells showed 8-fold greater resistance to the UCN-01-induce
d growth-inhibitory effect than the parent cells, SBC-3. No UCN-01-induced
GI accumulation in SBC-3 cells was observed in SBC-3/UCN cells and decrease
d expression of phosphorylated RE protein was found in SBC-3 cells. Neither
basal expression nor induction of p21(Cip1) by UCN-01 treatment was detect
ed in the SBC-3/UCN cell line. An inhibitory effect of UCN-01 on CDK2 activ
ity, which is mediated by p21(Cip1)/CDK2 complex formation upon UCN-01 trea
tment, was observed in SBC-3 but not in SBC-3/UCN cells. SBC-3/ UCN showed
higher CDK6 activity than SBC-3 cells. UCN-01 did not inhibit the CDK4 and
CDK6 activities in both cells. We screened the cell cycle regulatory molecu
les associated with G(1)/S progression and found a remarked decrease in int
erferon regulatory factor I (IRF-I), which is known to cooperate with p53 i
n p21(Cip1) induction. Our results suggest that p21(Cip1) regulation via th
e IRF-I-associated pathway may represent a major determinant of UCN-01-indu
ced growth inhibition in human lung cancer cells. Int. J. Cancer 85:275-280
, 2000. (C) 2000 Wiley-Liss, Inc.